PL3183236T3 - Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma - Google Patents
Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psmaInfo
- Publication number
- PL3183236T3 PL3183236T3 PL15753692.1T PL15753692T PL3183236T3 PL 3183236 T3 PL3183236 T3 PL 3183236T3 PL 15753692 T PL15753692 T PL 15753692T PL 3183236 T3 PL3183236 T3 PL 3183236T3
- Authority
- PL
- Poland
- Prior art keywords
- psma
- tracer
- preparation
- production
- active esters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14182053 | 2014-08-24 | ||
EP14183635.3A EP2993171A1 (en) | 2014-09-04 | 2014-09-04 | Method for the production of 18F-labeled PSMA-specific PET-tracers |
PCT/EP2015/069356 WO2016030329A1 (en) | 2014-08-24 | 2015-08-24 | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3183236T3 true PL3183236T3 (pl) | 2022-07-18 |
Family
ID=53938345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15753692.1T PL3183236T3 (pl) | 2014-08-24 | 2015-08-24 | Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma |
Country Status (5)
Country | Link |
---|---|
US (1) | US10112974B2 (pl) |
EP (1) | EP3183236B1 (pl) |
ES (1) | ES2912753T3 (pl) |
PL (1) | PL3183236T3 (pl) |
WO (1) | WO2016030329A1 (pl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3858347A3 (en) | 2007-08-17 | 2021-12-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
MX2015006109A (es) | 2012-11-15 | 2016-02-05 | Endocyte Inc | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. |
RS65324B1 (sr) | 2013-10-18 | 2024-04-30 | Novartis Ag | Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
BR112018005899A2 (pt) | 2015-09-30 | 2018-10-16 | Deutsches Krebsforschungszentrum | composto e composição farmacêutica |
GB201518918D0 (en) * | 2015-10-26 | 2015-12-09 | Norsk Medisinsk Syklotronsenter As And Uni I Oslo | Method |
AU2017238181B2 (en) * | 2016-03-22 | 2021-05-27 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
KR20230111272A (ko) | 2016-06-10 | 2023-07-25 | 더 존스 홉킨스 유니버시티 | 방사성 표지된 전립선-특이적 막 항원(PSMA) 억제제[18F]DCFPyL의 개선된 합성 |
WO2018022603A1 (en) * | 2016-07-25 | 2018-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof |
CA3030907A1 (en) | 2016-08-10 | 2018-02-15 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
WO2018098390A1 (en) * | 2016-11-23 | 2018-05-31 | Cancer Targeted Technology Llc | Albumin-binding psma inhibitors |
WO2018169942A1 (en) * | 2017-03-13 | 2018-09-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of synthesizing 18f radiolabeled biomolecular agents |
US11478558B2 (en) * | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
EP3765097B1 (en) | 2018-03-16 | 2022-04-27 | Universität zu Köln | 2-alkoxy-6-[18f]fluoronicotinoyl substituted lys-c(o)-glu derivatives as efficient probes for imaging of psma expressing tissues |
KR20230009399A (ko) * | 2020-05-11 | 2023-01-17 | 더 스쿨 코포레이션 칸사이 유니버시티 | 화합물 및 그의 제조방법, 산발생제, 조성물, 레지스트막, 하층막, 패턴 형성방법, 및 광학물품 |
CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2097111T1 (sl) | 2006-11-08 | 2016-02-29 | Molecular Insight Pharmaceuticals, Inc. | Heterodimeri glutaminske kisline |
CN101784192B (zh) | 2007-06-26 | 2015-03-18 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
EP2062630A1 (en) | 2007-11-20 | 2009-05-27 | Trasis S.A. | Method for the direct elution of reactive 18F fluoride from an anion exchange resin in an organic medium by the use of strong organic bases |
CA2987744C (en) | 2008-08-01 | 2022-11-15 | The Johns Hopkins University | Psma-binding agents and uses thereof |
HRP20221195T1 (hr) | 2009-03-19 | 2022-12-09 | The Johns Hopkins University | Spojevi koji ciljaju psma i njihova uporaba |
GB0905438D0 (en) * | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
-
2015
- 2015-08-24 WO PCT/EP2015/069356 patent/WO2016030329A1/en active Application Filing
- 2015-08-24 EP EP15753692.1A patent/EP3183236B1/en active Active
- 2015-08-24 PL PL15753692.1T patent/PL3183236T3/pl unknown
- 2015-08-24 US US15/506,351 patent/US10112974B2/en active Active
- 2015-08-24 ES ES15753692T patent/ES2912753T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
US20170267717A1 (en) | 2017-09-21 |
ES2912753T3 (es) | 2022-05-27 |
EP3183236B1 (en) | 2022-04-20 |
EP3183236A1 (en) | 2017-06-28 |
US10112974B2 (en) | 2018-10-30 |
WO2016030329A1 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3183236T3 (pl) | Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma | |
IL250511A0 (en) | Crystalline forms of ibrutinib | |
IL249968B (en) | Preparation of a test site | |
HK1244783A1 (zh) | 製造曲前列素和曲前列素衍生物的前藥的方法 | |
SG10201601042PA (en) | Production of ester mixtures | |
HUP1400475A2 (en) | Novel process for preparation of treprostinil and its salts | |
HK1231404A1 (zh) | 禁食條件下的他司美瓊的施用 | |
EP3166617C0 (en) | POLOXAMER COMPOSITION FREE FROM LONG CIRCULATION MATERIAL, METHODS OF PREPARATION AND USES | |
HK1257768A1 (zh) | Eb1作為藥物應答的生物標記物的用途 | |
HK1243995A1 (zh) | α-細辛醇酯及其製備方法與應用 | |
HUE058726T2 (hu) | Új nilotinib sók és azok polimorfjai | |
PL3110249T3 (pl) | Sposób wytwarzania mikrokapsułek biobójczych | |
ZA201707704B (en) | Production of vcl4 | |
SG11201505385VA (en) | Pharmaceutical composition in the form of a tabletand a method for producing same | |
SG11201608422VA (en) | Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof | |
IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
EP3221320A4 (en) | A process for the preparation of ibrutinib | |
PL2977373T3 (pl) | Sposób katalitycznego wytwarzania estrów | |
IL237572A0 (en) | Process and intermediates for the preparation of dastinib | |
IL251099A0 (en) | A salt of phenylglycine methyl ester | |
GB2544228B (en) | Production Method of Joint Material | |
HK1258181A1 (zh) | 製備螯合劑的方法 | |
HK1198611A2 (en) | A structure of bracelets connection | |
TWM490349U (en) | Improved structure of a darter | |
AU358389S (en) | Pharmaceutical capsule |